Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AgEagle Aerial Systems Inc.UAVS · Entity 7056 | Director | March 31, 2018 | May 21, 2019 |
| DIH HOLDING US, INC.DHAI · Entity 75642 | Director | August 04, 2025 | August 11, 2025 |
| Expion Energy, Inc.XPON · Entity 8198 | Director | August 13, 2026 | August 26, 2026 |
| Microbot Medical Inc.MBOT · Entity 6767 | Director | April 01, 2026 | April 03, 2026 |
| Trailblazer Merger Corp ITBMCU · Entity 86791 | Chief Financial Officer | March 28, 2023 | March 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AgEagle Aerial Systems Inc.
Report date March 31, 2018 · Filed May 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 60,724 |
Reported balance
After 2018-12-04 transaction · row 1
1 source rowRow 1 · 2018-12-04 · Conversion · Acquired 60,724 · Balance 60,724 F1: Mr. Scott Burell exercised 60,724 options on December 4, 2018 at an exercise price of $0.06 per share. |
| Options to purchase common stock, par value $0.001 per shareSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 | Direct | 66,132 |
Reported balance
After 2018-12-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-04 · Tax withholding · Disposed 60,724 · Balance 66,132 F1: Mr. Scott Burell exercised 60,724 options on December 4, 2018 at an exercise price of $0.06 per share. |
| Options to purchase common stock, par value $0.001 per shareSEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2023-09-29 | Direct | 126,856 |
Reported balance
After 2018-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-09-30 · Grant · Acquired 16,500 · Balance 126,856 F2: The options were issued as incentive compensation for services under the Company's Omnibus Equity Incentive Plan. F3: The options become exercisable on the Transaction Date and vest over a two-year period. |
| Options to purchase common stock, par value $0.001 per shareSEC Table II · derivative / convertible security · Conversion / exercise price $1.82 · Expires 2023-06-29 | Direct | 110,356 |
Reported balance
After 2018-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-06-30 · Grant · Acquired 16,500 · Balance 110,356 F2: The options were issued as incentive compensation for services under the Company's Omnibus Equity Incentive Plan. F3: The options become exercisable on the Transaction Date and vest over a two-year period. |
| Options to purchase common stock, par value $0.001 per shareSEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2023-03-30 | Direct | 93,856 |
Reported balance
After 2018-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-31 · Grant · Acquired 16,500 · Balance 93,856 F2: The options were issued as incentive compensation for services under the Company's Omnibus Equity Incentive Plan. F3: The options become exercisable on the Transaction Date and vest over a two-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Scott Burell exercised 60,724 options on December 4, 2018 at an exercise price of $0.06 per share.
F2: The options were issued as incentive compensation for services under the Company's Omnibus Equity Incentive Plan.
F3: The options become exercisable on the Transaction Date and vest over a two-year period.
DIH HOLDING US, INC.
Report date August 04, 2025 · Filed August 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2025-08-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Expion Energy, Inc.
Report date August 13, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,333 |
Reported balance
After 2026-08-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-13 · Grant · Acquired 5,000 · Balance 8,333 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. The RSUs vested in full on the grant date. F2: Includes (i) 5,000 shares of Common Stock, and (ii) 3,333 RSUs which are subject to vesting as previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. The RSUs vested in full on the grant date.
F2: Includes (i) 5,000 shares of Common Stock, and (ii) 3,333 RSUs which are subject to vesting as previously reported.
Microbot Medical Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.37 · Expires 2036-04-01 | Direct | 10,000 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 10,000 · Balance 10,000 |
Trailblazer Merger Corp I
Report date March 28, 2023 · Filed March 28, 2023
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CombiMatrix Corp
Report date November 14, 2017 · Filed November 16, 2017
Section 16 reporting ended · disclosed 2017-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-11-14 transaction · row 1
1 source rowRow 1 · 2017-11-14 · Disposition to issuer · Disposed 27,368 · Balance 0 F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 23,786 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 23,786 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 26, 2026 01:56 UTC | Expion Energy, Inc. XPON · Entity 8198 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001903596-26-000320 · ownership.xml · nonDerivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. The RSUs vested in full on the grant date. F2 · balance_after: Includes (i) 5,000 shares of Common Stock, and (ii) 3,333 RSUs which are subject to vesting as previously reported. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001493152-26-015151 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.01 per share · 10,000 shares Expires 2036-04-01 Read SEC document |
| October 16, 2025 Filed Oct 22, 2025 00:35 UTC | Expion Energy, Inc. XPON · Entity 8198 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001903596-25-000497 · ownership.xml · nonDerivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $60,000 of shares of Common Stock as determined by the closing price on the grant date, October 16, 2025. The RSUs shall vest in full on October 16, 2026, subject to the Reporting Person's continued service as a director on the Company's board of directors through the vesting date. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001493152-25-004278 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.01 per share · 10,000 shares Expires 2035-01-28 Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 21:15 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 74,218 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-23-039530 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,218 Underlying: Common Stock, par value $0.01 per share · 74,218 shares Expires 2033-11-02 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 10:36 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 16,637 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001493152-22-026611 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,637 Underlying: Common Stock, par value $0.01 per share · 16,637 shares Expires 2032-09-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:20 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024674 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:15 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0001493152-20-020845 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock, par value $0.01 per share · 2,771 shares Expires 2030-11-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on May 5, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 23:14 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015936 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:47 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000866 · ownership.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 04, 2018 Filed May 21, 2019 22:48 UTC | AgEagle Aerial Systems Inc. UAVS · Entity 7056 | Tax withholdingOptions to purchase common stock, par value $0.001 per share · Derivative | 60,724 | Not disclosed Strike: $0.06 | Not disclosed |
DisclosureSEC source: 0001575705-19-000066 · burell_4.xml · derivative · entry 2 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,132 Underlying: Common Stock · 60,724 shares Expires not disclosed F1 · price: Mr. Scott Burell exercised 60,724 options on December 4, 2018 at an exercise price of $0.06 per share. F1 · derivative.exercise_date: Mr. Scott Burell exercised 60,724 options on December 4, 2018 at an exercise price of $0.06 per share. F1 · derivative.expiration_date: Mr. Scott Burell exercised 60,724 options on December 4, 2018 at an exercise price of $0.06 per share. Read SEC document |
| December 04, 2018 Filed May 21, 2019 22:48 UTC | AgEagle Aerial Systems Inc. UAVS · Entity 7056 | ConversionCommon Stock, par value $0.001 per share | 60,724 | $0.06 | $3,643.44 |
DisclosureSEC source: 0001575705-19-000066 · burell_4.xml · nonDerivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Mr. Scott Burell exercised 60,724 options on December 4, 2018 at an exercise price of $0.06 per share. Read SEC document |
| September 30, 2018 Filed May 21, 2019 22:48 UTC | AgEagle Aerial Systems Inc. UAVS · Entity 7056 | GrantOptions to purchase common stock, par value $0.001 per share · Derivative | 16,500 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001575705-19-000066 · burell_4.xml · derivative · entry 3 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,856 Underlying: Common Stock · 16,500 shares Expires 2023-09-29 F2 · price: The options were issued as incentive compensation for services under the Company's Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: The options become exercisable on the Transaction Date and vest over a two-year period. Read SEC document |
| June 30, 2018 Filed May 21, 2019 22:48 UTC | AgEagle Aerial Systems Inc. UAVS · Entity 7056 | GrantOptions to purchase common stock, par value $0.001 per share · Derivative | 16,500 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0001575705-19-000066 · burell_4.xml · derivative · entry 4 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,356 Underlying: Common Stock · 16,500 shares Expires 2023-06-29 F2 · price: The options were issued as incentive compensation for services under the Company's Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: The options become exercisable on the Transaction Date and vest over a two-year period. Read SEC document |
| March 31, 2018 Filed May 21, 2019 22:48 UTC | AgEagle Aerial Systems Inc. UAVS · Entity 7056 | GrantOptions to purchase common stock, par value $0.001 per share · Derivative | 16,500 | Not disclosed Strike: $4.33 | Not disclosed |
DisclosureSEC source: 0001575705-19-000066 · burell_4.xml · derivative · entry 5 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,856 Underlying: Common Stock · 16,500 shares Expires 2023-03-30 F2 · price: The options were issued as incentive compensation for services under the Company's Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: The options become exercisable on the Transaction Date and vest over a two-year period. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:07 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 38,095 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-014423 · form4.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,095 Underlying: Common Stock, par value $0.01 per share · 38,095 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 17:53 UTC | CombiMatrix Corp CBMX · Entity 171845 | Disposition to issuerCommon Stock | 27,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-014224 · edgar.xml · nonDerivative · entry 1 Burell Scott R · CIK 0001399318 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 23,786 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 18:17 UTC | CombiMatrix Corp CBMX · Entity 171845 | SaleCommon Stock | 185 | $4.10 | $758.50 |
DisclosureSEC source: 0001179110-17-003198 · edgar.xml · nonDerivative · entry 1 Burell Scott R · CIK 0001399318 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,332 F1 · shares: Represents a portion of vested restricted stock unit shares that were sold pursuant to a previously adopted Rule 10b5-1 trading plan solely to pay required applicable withholding taxes. F2 · balance_after: Does not include 23,036 shares of common stock underlying restricted stock units that were previously reported but that are unvested. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 19:07 UTC | CombiMatrix Corp CBMX · Entity 171845 | SaleCommon Stock | 332 | $2.85 | $946.20 |
DisclosureSEC source: 0001179110-17-000924 · edgar.xml · nonDerivative · entry 1 Burell Scott R · CIK 0001399318 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,376 F1 · shares: Represents a portion of vested restricted stock unit shares that were sold pursuant to a previously adopted Rule 10b5-1 trading plan solely to pay required applicable withholding taxes. F2 · balance_after: Does not include 24,177 shares of common stock underlying restricted stock units that were previously reported but that are unvested. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 17:45 UTC | CombiMatrix Corp CBMX · Entity 171845 | GrantCommon Stock | 19,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033326 · edgar.xml · nonDerivative · entry 1 Burell Scott R · CIK 0001399318 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,426 F1 · price: The reported common stock underlies restricted stock units that were granted to the reporting person for no consideration. The restricted stock units vest in four equal annual installments beginning December 16, 2017. F2 · balance_after: Includes the 19,110 unvested shares of common stock underlying the current reported restricted stock unit grant, but does not include 6,457 remaining unvested shares of common stock underlying previously reported restricted stock unit grants. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.